Novel GBE1 mutation in a Japanese family with adult polyglucosan body disease
Citation Manager Formats
Make Comment
See Comments

Adult polyglucosan body disease (APBD) is an autosomal recessive leukoencephalopathy caused by a deficiency of glycogen branching enzyme (GBE), leading to deposition of PBs in the central and peripheral nervous systems. The main clinical features are adult-onset progressive neurogenic bladder dysfunction, gait disturbance, and peripheral neuropathy.1 The majority of patients with APBD are of Ashkenazi Jewish ancestry and have a common p.Tyr329Ser mutation in the GBE1 gene encoding GBE.1,2 We identified a novel GBE1 mutation in a Japanese family with APBD using exome sequencing.
Case reports.
Two brothers (patients 1 and 2, 72 and 66 years old, respectively) were admitted to our hospital because of gait disturbance. Ages at onset were 70 and 62 years, respectively. Their family history revealed consanguinity with their parents being first cousins. Both patients showed muscle weakness with atrophy in the legs and generalized hyporeflexia. Extensor plantar reflexes and myoclonus of the legs were observed in patient 1, while ophthalmoplegia, bulbar palsy, and sensory disturbance of the distal lower extremities and urinary incontinence were present in patient 2. Their Mini-Mental State Examination scores were 28/30 and 19/30, respectively, indicating slight executive dysfunction in patient 2.
Glycated hemoglobin revealed diabetes mellitus in patient 1. Both patients showed normal findings in the CSF. T2-weighted sagittal MRIs of both patients showed atrophy of the medulla and the spinal cord. MRI with fluid-attenuated inversion recovery axial sequences demonstrated hyperintense white matter abnormalities, predominantly in the periventricular regions and posterior limb of the internal capsule, as well as pyramidal tracts and medial lemniscus of the pons and the medulla (figure, A). Nerve conduction studies indicated the findings of axonal sensory-motor neuropathy, predominantly in the lower limbs.
(A) Brain MRIs of patient 1 (A.a, A.b) and patient 2 (A.c, A.d) showed atrophy of the medulla and the spinal cord (A.a and A.c, sagittal T2-weighted images), and hyperintense white matter lesions in the periventricular regions, posterior portions of the internal capsule, pyramidal tracts, and medial lemniscus of the pons and medulla (A.b and A.d, respectively, axial fluid-attenuated inversion recovery images). (B) Sanger sequencing confirmed that the A to G transition at position 929 (c.929A>G), with replacement of tyrosine with cysteine at codon 310 (p.Tyr310Cys), was in a homozygous state in patients 1 and 2, and a heterozygous state in their sister. (C) The affected amino acid is highlighted by the yellow rectangle. This tyrosine at position 310 is highly conserved among mammals but not in other species. (D) Axial sections of the sural nerve biopsy specimen of patient 1 showed several round periodic acid–Schiff (PAS)-positive PBs (D.a and D.b, scale bar = 25 μm). Axial epoxy section showed a large intra-axonal PB and loss of myelinated fibers (D.c, toluidine blue, scale bar = 25 μm). PB, polyglucosan body.
To explore the genetic cause of the disease, after obtaining informed consent, we performed exome sequencing for the brothers as well as their younger sister, who was asymptomatic and neurologically intact. A novel homozygous c.929A>G missense mutation (p.Tyr310Cys) in the GBE1 gene was identified in patients 1 and 2. This variant was also present in the sister with a heterozygous state. Sanger sequencing of the PCR product containing the exon 7 region of the GBE1 gene validated the presence of this homozygous mutation in the brothers and the heterozygous mutation in their sister (figure, B). This variant affects a highly conserved amino acid found within the GBE protein (figure, C). The diagnosis of APBD was made by confirming the intra-axonal deposition of PB in the sural nerve biopsy specimen from patient 1 (figure, D).
Discussion.
In the present patients, we identified a novel homozygous c.929A>G mutation in the GBE1 gene (p.Tyr310Cys). We consider that this is a disease-causing mutation, as their asymptomatic sister was found to carry it with a heterozygous state and did not show any neurologic abnormalities. This mutation was not found in 800 healthy individuals and known to affect an amino acid residue conserved among mammals. This is the report of Japanese patients with genetically confirmed APBD.
To date, 19 different mutations in the GBE1 gene have been found to cause APBD, all of which are missense mutations except for 1 frameshift, 1 splice site, and 1 intronic indels mutations.1,–,7 These GBE1 missense mutations localized in the catalytic core of GBE result in disrupting protein structure or affecting catalysis. The most common mutation is p.Tyr329Ser (c.986A>C), which was reported in Ashkenazi Jewish patients.1,2 More recently, novel missense mutations were detected in non-Jewish patients including Italians and Germans.4,–,6 They demonstrated atypical symptoms, such as episodic vomiting, hearing loss, or unilateral plexopathy, respectively.4,–,6 Ophthalmoplegia and bulbar palsy observed in patient 2 were very rare or atypical symptoms of APBD. These clinical features of patient 2 were quite different from those of patient 1, although both patients showed muscle weakness and hyporeflexia, indicating intrafamilial variability. These findings suggest clinical heterogeneity of APBD especially in non-Jewish patients including Japanese.
By contrast, medullary and spinal atrophy, periventricular white matter abnormalities with lesions in the posterior limb of the internal capsule, pyramidal tracts, and medial lemniscus of the pons and medulla, which were observed in our patients, are characteristic MRI features of patients with APBD.1 These neuroradiologic findings are useful for diagnosing APBD in patients with an unknown etiology of leukoencephalopathy.
As exome sequencing is becoming a less expensive and more reliable method for detecting inherited disorders, it is more efficient than whole-genome sequencing. Our study reconfirmed the diagnostic utility of exome sequencing in a family with a rare and atypical neurologic disorder.
Footnotes
Study funding: This work was supported in part by KAKENHI (Grant-in-Aid for Scientific Research on Innovative Areas [22129001 and 22129002]), a Grant-in-Aid (H26-Itaku[Nan]-Ippan-006) from the Ministry of Health, Labour and Welfare.
Disclosure: Dr. Harigaya reports no disclosures. Dr. Matsukawa received funds from JSPS KAKENHI grant number 15H06160 and GlaxoSmithKline. Dr. Fujita and Dr. Mizushima report no disclosures. Dr. Ishiura has received speaker honoraria from Sanofi and Sumitomo Dainippon Pharma; and has received research support from a Grant-in-Aid for Young Scientists (Startup, 24890044), a fund from The Cell Science Research Foundation, and a Grant-in-Aid for Young Scientists (B, 15K20941). Dr. Mitsui was funded by JSPS KAKENHI grant numbers 25860700 and 15K09334. Dr. Morishita was funded by KAKENHI (Grants-in-Aid for Scientific Research on Innovative Areas [22129008 and 221 S0002]) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and has served on the editorial boards of the Journal of BMC Genomics and the Journal of Bioinformatics and Computational Biology. Dr. Shoji was funded by KAKENHI (Grants-in-Aid for Scientific Research [C, 15K09306]) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Amyloidosis Research Committee, and the Longevity Science Committee of the Ministry of Health and Welfare of Japan. Dr. Ikeda was funded by KAKENHI (Grants-in-Aid for Scientific Research [C, 16K09665]) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Dr. Tsuji was funded by KAKENHI (Grants-in-Aid for Scientific Research on Innovative Areas [22129001 and 22129002]) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and a grant-in-aid (H26-Itaku[Nan]-Ippan-006) from the Ministry of Health, Labour and Welfare (MHLW). Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was paid by the authors.
- Received November 17, 2016.
- Accepted in final form January 24, 2017.
- Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
- 1.↵
- 2.↵
- 3.↵
- 4.↵
- Colombo I,
- Pagliarani S,
- Testolin S, et al
- 5.↵
- 6.↵
- Naddaf E,
- Kassardjian CD,
- Kurt YG,
- Akman HO,
- Windebank AJ
- 7.↵
- Akman HO,
- Kakhlon O,
- Coku J, et al
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.